Steroid receptors in breast cancer

Balkees Abderrahman, V. Craig Jordan

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Abstract

The estrogen receptor (ER) is the most important member of the nuclear receptor superfamily that controls the replication or apoptotic death of selected populations of breast cancer cells. The progesterone receptor is an estrogen-regulated protein in breast cancer that plays a role in predicting the hormone dependence of metastatic breast cancer. The mechanism of action of all effective antihormonal agents (tamoxifen, fulvestrant, aromatase inhibitors) is mediated through the ER signal transduction pathway and prevents estrogen action in the tumor cell. Tamoxifen is the pioneering selective ER modulator (SERM) that has estrogen-like effects in bone and the cardiovascular system, but antiestrogenic actions in breast cancer. The monthly depot injectable fulvestrant is a selective ER downregulator (SERD) that destroys the tumor ER and ERs throughout postmenopausal patient's body. There is a current search for an orally active SERD.

Original languageEnglish (US)
Title of host publicationThe Breast
Subtitle of host publicationComprehensive Management of Benign and Malignant Diseases
PublisherElsevier Inc.
Pages272-281.e2
ISBN (Print)9780323359559
DOIs
StatePublished - 2018

Keywords

  • Androgen receptor
  • Aromatase inhibitors
  • Estrogen receptor
  • Estrogen-induced apoptosis
  • Fulvestrant
  • Glucocorticoid receptor
  • Progesterone receptor
  • Selective estrogen receptor downregulator
  • Selective estrogen receptor modulator
  • Tamoxifen

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Steroid receptors in breast cancer'. Together they form a unique fingerprint.

Cite this